Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Journal Article


Authors: Cuzick, J.; Berney, D. M.; Fisher, G.; Mesher, D.; Møller, H.; Reid, J. E.; Perry, M.; Park, J.; Younus, A.; Gutin, A.; Foster, C. S.; Scardino, P.; Lanchbury, J. S.; Stone, S.
Article Title: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort
Abstract: Background: The natural history of prostate cancer is highly variable and it is difficult to predict. We showed previously that a cell cycle progression (CCP) score was a robust predictor of outcome in a conservatively managed cohort diagnosed by transurethral resection of the prostate. A greater need is to predict outcome in patients diagnosed by needle biopsy. Methods: Total RNA was extracted from paraffin specimens. A CCP score was calculated from expression levels of 31 genes. Clinical variables consisted of centrally re-reviewed Gleason score, baseline prostate-specific antigen level, age, clinical stage, and extent of disease. The primary endpoint was death from prostate cancer. Results :In univariate analysis (n=349), the hazard ratio (HR) for death from prostate cancer was 2.02 (95% CI (1.62, 2.53), P<10 -9) for a one-unit increase in CCP score. The CCP score was only weakly correlated with standard prognostic factors and in a multivariate analysis, CCP score dominated (HR for one-unit increase1.65, 95% CI (1.31, 2.09), P3 × 10 -5), with Gleason score (P=5 × 10 -4) and prostate-specific antigen (PSA) (P=0.017) providing significant additional contributions. Conclusion: For conservatively managed patients, the CCP score is the strongest independent predictor of cancer death outcome yet described and may prove valuable in managing clinically localised prostate cancer. © 2012 Cancer Research UK All rights reserved.
Keywords: human tissue; aged; major clinical study; cancer staging; neoplasm staging; adenocarcinoma; prostate specific antigen; cell cycle; cell cycle progression; cohort studies; proportional hazards models; cancer mortality; gleason score; prostate-specific antigen; prostatic neoplasms; disease severity; conservative treatment; biopsy, needle; needle biopsy; prognostic factors; multivariate analysis; prostate adenocarcinoma; rna extraction; paraffin; kaplan-meier estimate; transurethral resection of prostate; expression profiles; ccp score; cell cycle genes; localised prostate cancer; neoplasm grading
Journal Title: British Journal of Cancer
Volume: 106
Issue: 6
ISSN: 0007-0920
Publisher: Nature Publishing Group  
Date Published: 2012-03-13
Start Page: 1095
End Page: 1099
Language: English
DOI: 10.1038/bjc.2012.39
PROVIDER: scopus
PMCID: PMC3304411
PUBMED: 22361632
DOI/URL:
Notes: --- - "Export Date: 2 April 2012" - "CODEN: BJCAA" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Peter T Scardino
    639 Scardino